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Background: Breast carcinomas can be classified into five subtypes based on gene expression profiling or
immunohistochemical characteristics. Among these subtypes, basal-like breast carcinomas (BLBCs) are one of the
most studied group, due to their poor prognosis. The aim of this study was to investigate the prevalance,
morphological and immunohistochemical features of BLBCs, in Turkish population.
Methods: Five hundred invasive breast carcinomas were reviewed for several morphological features and
immunostained for oestrogen and progesterone receptors, c-ERB-B2, cytokeratin5/6, cytokeratin14, vimentin and
epidermal growth factor receptor (EGFR). Basal-like breast carcinoma was defined as a triple negative tumor with
cytokeratin5/6 and/or EGFR positive.
Results: The prevalance of BLBC was 9.6%. All medullary carcinomas and 55.6% of metaplastic carcinomas showed
basal-like immunophenotype. Patients with BLBC were younger (p=0.04) and had higher-grade tumors (p<0.0001).
Morphologic features associated with BLBC included increased mitosis, nuclear pleomorphism, presence of
geographic and/or central necrosis, pushing margin of invasion and stromal lymphocytic response (p<0.0001).
Presence of prominent nucleoli and vesicular nuclear chromatin were the cytological features correlated with
basal-like phenotype (p<0.0001). On multivariate analyses, BLBCs were associated with high mitotic number
(p<0.0001), the presence of vesicular chromatin (p=0.004), high tubular grade (p=0.011), lymphocytic response
(p=0.031) and the absence of carcinoma insitu (p=0.039). Vimentin was positive in 53.2% of BLBCs, while
cytokeratin14 was less frequently expressed (27.7%).
Conclusions: BLBCs have some distinctive, but not pathognomonical, morphological features. Paying attention to
these features and adding cytokeratin14 and vimentin to the immunohistochemical panel can help the definitive
diagnosis of BLBCs.
Virtual slide: Http://www.diagnosticpathology.diagnomx.eu/vs/5962175467857400
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Breast cancer is the most frequent non-cutaneous neo-
plasia in women and second cause of death [1]. Breast
carcinomas are heterogeneous disease such that they
may have different prognoses and therapy responses des-
pite similarities in histological types, grade and stage. Al-
though there are 19 subtypes of breast carcinoma
according to World Health Organization (WHO) 2003* Correspondence: erdoganasli@gmail.com
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reproduction in any medium, provided the orclassification [2], it does not entirely include the various
clinical courses of this disease. Based on the distinct mo-
lecular signatures, gene expression analysis of breast car-
cinomas has demonstrated 5 different classes; as luminal
A, luminal B, normal breast like, HER2 negative and
basal-like. Recently, at 12th St Gallen International
Breast Cancer conference, these subtypes are reclassified
as luminal A, luminal B (HER2 negative), luminal B
(HER2 positive), HER2 positive (nonluminal) and triple
negative (ductal) according to therapeutic options [3].
These classes usually correlate with prognosis [4,5].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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researchers because of its unfavorable prognosis and lim-
ited therapy opportunities. The BLBCs constitute approxi-
mately 15% of invasive breast cancers [6]. These tumors
occur frequently in premenopausal young patients [7].
They are associated with larger tumor size and distinctive
histological features, including high histological grade with
high mitotic rate and nuclear/cytoplasmic ratio, the pres-
ence of spindle cell or squamous metaplasia, pushing
growth pattern, central acellular areas of hyalinization or
necrosis and lymphocytic infiltrate [7-10]. Medullary and
atypical medullary carcinomas, myoepithelial carcinomas
and metaplastic carcinomas may also show the phenotype
of basal-like carcinomas [8].
Basal-like breast carcinomas have variable expressions
of basal cytokeratins (CKs) (CK5/6, CK14, CK17),
vimentin, myoepithelial markers (smooth muscle actin,
p-63), CD117, P-cadherin and/or human EGFR (HER1/
EGFR) [8-13]. They are usually negative for oestrogen
receptor (ER), progesterone receptor (PR) and c-ERB-B2
(so they are called triple negative, TN). Since not all TN
carcinomas are basal-like, BLBC is not synonymous to
TN carcinoma [14]. It has been also shown that BLBCs
are associated with mutations in BRCA-1, TP53 and pro-
teins involved in the p16/retinoblastoma pathway and
met oncogene overexpression [15-18].
The gold standard of defining the BLBC is using gene
expression profile (GEP) but currently using GEP is still
limited due to financial concerns during daily routine;
therefore immunohistochemical (IHC) markers have
been used instead of the gene analyses [7,10,11]. It has
been shown that a panel with four antibodies including
ER, c-ERB-B2, EGFR and CK5/6 achieved to define
BLBC with 55-76% sensitivity and 100% specificity
[10,11]. Carey et al. updated this panel by adding PR,
which is regulated by ER gene, therefore positive in most
of the ER+ tumors [7]. They have defined BLBCs as ER-,
PR-, c-ERB-B2-, CK5/6 and /or EGFR+ tumors [7].
To the authors’ knowledge, clinicopathological charac-
teristics of BLBC with detailed morphological evaluation
have not been studied in Turkish population before. The
aim of this study is to determine the incidence of BLBCs
and to define their morphological and immunohisto-
chemical features by comparing them with the other
types of breast carcinomas.
Methods
Case selection
Four hundred and sixty eight (468) consecutive invasive
breast carcinoma patients, who underwent modified rad-
ical mastectomy, lumpectomy and excisional biopsy with
or without lymph node dissection, from 2006 to 2010,
were retrieved from the files of our institution. The
patient’s age and gender, tumor size, surgical proceduretype, the presence or absence of tumor invasion in the
nipple, skin and fascia of the breast tissue were all noted
from the original pathology reports. The expression of
ER and PR of the tumors were determined by immuno-
histochemistry and c-ERB-B2 status of the tumor was
determined using immunohistochemistry and/or fluores-
cence insitu hybridization.
The ethical review committee of Gazi University
School of Medicine approved the study.
Morphologic parameters
Two pathologist, an experienced senior pathologist and
a less experienced junior pathologist reevaluated all of
the tumor slides stained with hematoxylin and eosin
(HE) for the following morphological features and the
histological tumor type according to WHO 2003 classifi-
cation [2]. The morphological features were categorized
into 3 groups:
1.Grading factors: Histological grade was assessed using
the modified Bloom-Richardson method, in which
tubule formation/grade of the tumor, nuclear
pleomorphism/atypia (nuclear grade), mitotic count
were scored [19]. Mitotic count was performed on
Olympus BH2 light microscope, with a graticule at x40
magnification and in 10 high-power fields (HPFs).
Mitotic number was scored as 1 when it was between
0–7, 2 when between 8–14 and 3 when 15 or more.
2. Architectural features of the tumor:i. Tumor growth pattern was assessed as infiltrative if
there was irregular infiltration into the surrounding
parenchyma or fat or pushing if the tumor was well
circumscribed.
ii. Necrosis with its type was noted as present or
absent. Large confluent areas of tumor necrosis
with an irregular outline called as geographic
necrosis and the necrosis in the middle of the
tumor islands was called as central necrosis.
iii. Stromal lymphocytic response was scored as none,
mild (less than 25% of the tumor), moderate (25 to
50% of the tumor) and marked (>50% of the
tumor).
iv. Presence or absence of carcinoma insitu [20] was
determined.
v. Presence of central scar, defined as the central
fibrotic, sclerotic, predominantly acellular area of
tumor, was looked for.
3. Cytological features of the tumor cells:
i. Presence of nucleoli were scored as absent or
prominent if they were easily visible at low power.
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as scant, moderate or copious according to
nuclear-cytoplasm ratio.
iii. Presence of vesicular chromatin pattern was
noted.Tissue microarray
The specimens were routinely processed, formalin-fixed
and paraffin-embedded. Invasive tumors were marked
on HE stained slides for the construction of tissue
microarray (Veridiam advanced tissue arrayer, VTA-100,
USA). Each case was represented with 4 different 0.1 cm
cores in the array blocks.Immunohistochemistry
Cytokeratin 5/6, CK14, EGFR and vimentin were applied
on 5 μm tissue microarray sections. Sections were
dewaxed in xylene substitute and hydrated with a graded
series of ethanol concentrations and distillated water.
Antigen retrieval was obtained in tris-EDTA (pH: 9.0)
buffer for CK5/6 and citrate buffer (pH: 6.0) for EGFR,
CK14 and vimentin for 20 minutes in a microwave oven.
Sections were incubated with primary antibody solutions
for CK5/6 (monoclonal mouse anti-human, clone D5/16
B4, Dako, Denmark), EGFR (monoclonal mouse anti-
human, cloneE30, Dako), CK14 (monoclonal mouse
anti-human, clone SPM 263, Spring bioscience, CA,
USA) and vimentin (monoclonal mouse anti-human,
cloneV9, Dako, Denmark) at a dilution of 1:100 with
PBS for 1 hour at room temperature. After washing with
PBS, they were incubated with secondary antibody (multi-
species ultra streptavidine detection system-HRP, Zymed,
Massachusetts, USA) and streptavidin-biotin complex
(Zymed, Massachusetts, USA) for 20 minutes at room
temperature. For immunoreaction, diaminobenzidine (dia-
minobenzidinetetrachloride, Zymed, Massachusetts, USA)
was used as chromogen and sections were counterstained
using Harris hematoxylin. Staining was performed manu-
ally. For each antibody, the intensity and percentage of
staining were evaluated. Membranous staining for EGFR
and cytoplasmic staining for CK5/6, CK14 and vimentin
were noted. Tumors showing no staining were considered
as negative.
Oestrogen receptor, PR and c-ERB-B2 results were
noted from pathology reports. For ER and PR, nuclear
staining more than 1% was regarded as positive. c-ERB-
B2 overexpression was evaluated semiquantitatively and
scores from 0 to 3 were given according to the staining
intensity and the percentage of the positive tumor cells
for IHC [21]. Tumors with an IHC score of 3 and/or
with c-ERB-B2/CEP 17 ratio of equal or more than 2.2
in FISH analysis were regarded as positive for c-ERB-B2
amplification [21].Tumor classification
By using immunohistochemistry for expression profiling
of BLBCs according to the criteria of Carey et al., we
defined BLBC as ER, PR, c-ERB-B2 negative and CK5/6
and/or EGFR positive tumors [7]. The tumors that did
not fulfill these criteria were called nonbasal-like breast
carcinoma (NBBC).
Statistical analysis
Statistical analysis was performed using the SPSS 11.5
software program. Student’s t-test and Mann–Whitney
test were performed for the comparison of mean and
median values, respectively. Nominal variables were
compared using Pearson’s Chi-square test or Fisher’s
exact test. Morphological features, which were thought
to be predictive for BLBCs, were evaluated by univariate
logistic regression analyses. To determine the most sig-
nificant morphological features distinguishing BLBC
from NBBC, multivariate logistic regression analysis with
stepwise removal was used following the results obtained
from univariate statistical test. For each morphological
feature, the odds ratio and 95% confidence interval
was calculated. Statistical significance was defined as a
p-value less than 0.05 (p<0.05).
Results
Patients’ background
Four hundred sixty eight (468) breast carcinoma patients
were retrieved. Twenty-eight (28) patients had multifocal
tumors that were defined as the presence of more than
one well-delineated invasive tumor foci separated by un-
involved breast tissue, regardless of the distance between
foci. Thirteen (13) of 28 patients had contra lateral
breast carcinoma and another 12 had 2 foci, 2 had 3 foci
and 1 had 4 foci of carcinoma in the same breast. In
summary, a total of 500 tumors of 468 patients were
evaluated in this study.
Only 3 (0.6%) of the patients were male. Ninety-one
percent (91%) of the patients had mastectomy, 7.9% had
lumpectomy and 1.1% had excisional biopsy with or
without axillary lymph node dissection. Patients’ demo-
graphic data and tumor characteristics were summarized
in the Table 1.
The most frequent histological type was invasive ductal
carcinoma (IDC), which accounted for 81.6% of the
tumors (408/500). Other types were invasive lobular car-
cinoma (23/500, 4.6%), mixed carcinoma (9 ductal+lobu-
lar, 2 ductal+mucinous, 1 mucinous+neuroendocrine, 1
tubular+cribriform) (13/500, 2.6%), mucinous carcin-
oma (11/500, 2.2%), metaplastic carcinoma (9/500,
1.8%), papillary carcinoma (7/500, 1.4%), medullary
carcinoma (5/500, 1%), tubular carcinoma (5/500, 1%),
apocrine carcinoma (4/500, 0.8%), micropapillary car-
cinoma (4/500, 0.8%), signet ring cell carcinoma
Table 1 Demographic features and tumor characteristics of the patients with breast carcinoma
Total BLBC NBBC p value
Age (n=468) (n=45) (n=423)
Mean:53±12 (range: 19–86) years Mean:49.3±12.9 (range: 19–78) years Mean:53.3±12.7 (range: 27–86) years p=0.04
Tumor size (n=500) (n=47) (n=453)
Mean: 2.7±1.6 cm (0.4-20) Mean: 2.8±1.4 cm (1–8) Mean: 2.7±1.6 cm (0.4-20) p=0.47
Median: 2.5 cm Median: 2.5 cm Median: 2.4 cm
<2 cm 203 (40.6%) 12 (26.5%) 191 (42.2%) p=0.07
2-5 cm 275 (55%) 33 (70.2%) 242 (53.4%)
<5 cm 22 (4.4%) 2 (4.3%) 20 (4.4%)
Histological grade (n=500) (n=47) (n=453) p<0.0001
1 143 (28.6%) 0 (0%) 143 (31.6%)
2 175 (35%) 0 (0%) 175 (38.6%)




Mean: 5 (0–46) Mean: 6 (0–27) Mean: 5 (0–46) p=0.51
0 214 (43.8%) 20 (45.5%) 194 (43.6%) p=0.39
1-3 161 (32.9%) 16 (36.4%) 145 (32.6%)
4-9 74 (15.1%) 3 (6.8%) 71 (16%)
≥10 40 (8.2%) 5 (11.4%) 35 (7.8%)
Nipple invasion (n=456) (n=37) (n=419) p=0.53
Absent 34 (7.5%) 34 (91.9%) 388 (92.6%)
Present 422 (92.5%) 3 (8.1%) 31 (7.4%)
Breast skin invasion (n=500) (n=47) (n=453) p=0.16
Absent 15 (3%) 44 (93.6%) 441 (97.4%)
Present 485 (97%) 3 (6.4%) 12 (2.6%)
Fascia invasion (n=469) (n=43) (n=426) p=0.77
Absent 39 (8.3%) 39 (90.7%) 391 (91.8%)
Present 430 (91.7%) 4 (9.3%) 35 (8.2%)
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cribriform carcinoma (2/500, 0.4%) and neuroendo-
crine carcinoma (1/500, 0.2%) and atypical medullary
carcinoma (1/500, 0.2%).Light microscopic findings
Basal-like breast carcinoma (Figure 1).
Fortyfive (45) out of 468 patients had BLBC (9.6%)
and 79.7% of TN carcinomas were basal-like. All of the
patients were women. The average age for BLBCs was
49.3 ranging from 10 to 78 years.
For two patients with bilateral mastectomies, a tu-
mor in one side was BLBC while the other in the contra
lateral site was NBBC. Moreover, in a case with four
separate tumors in the same breast, only two foci
were BLBC. In total, 47 invasive breast tumors had
basal-like immunophenotype.The most common histological type was IDC (36/47,
76.6%). Rest of the BLBCs consisted of medullary carcin-
omas (5/47, 10.6%), metaplastic carcinomas (5/47,
10.6%) and pleomorphic carcinomas (1/47, 2.2%).
The average tumor size was 2.8 cm and 74.5% of the
basal-like tumors were larger than 2 cm. All BLBCs
showed histological grade of 3. None of the BLBCs had
a histological grading score of 7 and less. The majority
of tumors (44/47, 93.6%) showed solid architecture with-
out tubule formation. A high mitotic rate was identified
in most of the tumors, ranging from 8 to 60 mitoses/10
HPFs (average 25 mitoses/10 HPFs). All cases had a nu-
clear grade of 3, with the exception of one case (97.9%).
Most of the tumors had pushing borders (27/47,
57.5%) and 43/47 (91.5%) had some degree of stromal
lymphocytic response at the tumor edge. Geographic ne-
crosis was identified in 19/47 tumors (40.4%) whereas
central necrosis was observed in 31/47 cases (66%).
Figure 1 Morphological features of BLBCs (HE staining). A. Metaplastic carcinoma shows pushing growth and necrosis (x40). B. Medullary
carcinoma with marked lymphocytic response and lacking tubule formation (x200). C. Tumor shows large central necrosis (x200). D. Invasive
ductal carcinoma demonstrates moderate lymphocytic response and large central scar (x200). E. Tumor cells exhibit varying amount of cytoplasm,
numerous mitosis and nuclear atypia; most of the tumor cells have vesicular chromatin and prominent nucleoli (x400).
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and accompanying CIS (27/47, 57.4%).
In most of the tumors (41/47, 87.2%), cells revealed
vesicular chromatin pattern. Nucleoli were prominent in
41/47 (87.2%) cases. There were slight differences be-
tween the cytoplasmic amounts of the tumor cells.
The results are summarized in Table 2.Basal-like breast carcinoma versus nonbasal-like
breast carcinoma
Patients with BLBC were younger than with NBBC
(p=0.04). No statistical difference was shown for the
tumor size (p=0.47), the presence of lymph node metas-
tases (p=0.51) and nipple (p=0.53), skin (p=0.16) or
fascia invasion (p=0.77) between BLBCs and NBBCs.
Considering the grading factors, BLBCs had more mi-
totic figures (p<0.0001), more pleomorphic nuclei
(p<0.0001) and more solid architecture with less tubule
formation (p<0.0001) than NBBCs; in summary, BLBCs
were frequently higher grade (p<0.0001).
Comparison for architectural parameters showed that
BLBCs had more frequent central necrosis (p<0.0001),
geographic necrosis (p<0.0001) and pushing borders
(p<0.0001) than NBBCs. Accompanying CIS was rarely
present in BLBCs (p<0.0001). On the other hand,
moderate-severe lymphocytic response was seen more
frequently in BLBCs than NBBCs (p<0.0001). There wasno statistical difference for the presence of central scar
between BLBC and NBBC (p=0.68).
When cytological features were compared, having
prominent nucleoli and vesicular chromatin were signifi-
cantly associated with BLBC (p<0.0001 for both). No dif-
ference was observed for the amount of the tumor cell
cytoplasm between BLBCs and NBBCs (p=0.27).
The results are summarized in Table 2.
Univariate analyses revealed morphological features
associated with BLBCs. After stepwise removal of those
features not significant at 5% level, for multivariate logis-
tic regression analysis; five features remained in the
model: mitotic count, vesicular chromatin, tubular grade,
lymphocytic infiltration and absence of CIS (Table 3).
Immunohistochemical findings (Figure 2).
Immunohistochemical stains for CK5/6, CK14, EGFR
and vimentin were performed on 500 invasive breast
carcinomas. Table 4 summarized the IHC results.
As a definition of the BLBC in our study, all of the
BLBCs showed expression of CK5/6 and/or EGFR.
48.9% of BLBCs (23/47) were positive for both CK5/6
and EGFR. 46.8% of the cases (22/47) showed CK5/6
(+)/EGFR (−) profile, however, only 4.3% of cases (2/47)
were positive only for EGFR.
Cytokeratin 14 expression was identified in 27.7% (13/
47) of the BLBCs and its specificity was 92.3%. Vimentin
was expressed in 53.2% (25/47) of the BLBCs with a spe-
cificity of 90.5%. Both CK14 and vimentin expressions
Table 2 Morphologic features of the tumors and correlation with BLBCs
Total (n=500) BLBC (n=47) NBBC (n=453) p value Odds ratio (95% CI)
Mitotic number Mean: 11.5±9 Mean: 25±9 Mean: 10±8 p<0.0001 1.17 (1.12-1.21)
Median: 9 Median: 24 Median: 8
Range: 1-60 Range: 8-60 Range: 1-48
0-7 219 (43.8%) 0 (0%) 219 (48.3%)
8-14 131 (26.2%) 3 (6.4%) 128 (28.3%)
≥15 150 (30%) 44 (93.6%) 106 (23.4%)
Tubule formation p<0.0001 13.38 (4.31-44.69)
1 36 (7.2%) 0 (0%) 36 (8%)
2 203 (40.6%) 3 (6.4%) 200 (44.1%)
3 261 (52.2%) 44 (93.6%) 217 (47.9%)
Nuclear grade p<0.0001 42.80 (5.92-309.27)
1 54 (10.8%) 0 (0%) 54 (11.9%)
2 192 (38.4%) 1 (2.1%) 191 (42.2%)
3 254 (50.8%) 46 (97.9%) 208 (45.9%)
Central scar p=0.68
Present 157 (31.4%) 16 (34%) 141 (31.1%)
Absent 343 (68.6%) 31 (66%) 312 (68.9%)
Central necrosis p<0.0001 10.08 (5.24-19.38)
Present 104 (20.8%) 31 (66%) 73 (16.1%)
Absent 396 (79.2%) 16 (34%) 380 (83.9%)
Geographic necrosis p<0.0001 5.23 (2.73-10.02)
Present 71 (14.2%) 19 (40.4%) 52 (11.5%)
Absent 429 (85.8%) 28 (59.6%) 401 (88.5%)
CIS p<0.0001 5.29 (2.84-9.86)
Present 382 (76.2%) 20 (42.6%) 361 (79.7%)
Absent 119 (23.8%) 27 (57.4%) 92 (20.3%)
Stromal lymphocytic response p<0.0001 27.02 (8.71-83.92)
None 174 (34.8%) 4 (8.5%) 170 (37.5%)
Mild 158 (31.6%) 4 (8.5%) 154 (34%)
Moderate 114 (22.8%) 18 (38.3%) 96 (21.2%)
Marked 54 (10.8%) 21 (44.7%) 33 (7.3%)
Tumor growth p<0.0001 7.14 (3.80-13.42)
Pushing 99 (20%) 27 (57.5%) 72 (15.9%)
Infiltrative 401 (80%) 20 (42.6%) 381 (84.1%)
Prominent nucleol p<0.0001 10.36 (4.31-24.91)
Present 221 (44.2%) 41 (87.2%) 180 (39.7%)
Absent 279 (55.8%) 6 (12.8%) 273 (60.3%)
Vesicular chromatin p<0.0001 15.59 (6.47-37.59)
Present 179 (35.8%) 41 (87.2%) 138 (30.5%)
Absent 321 (64.2%) 6 (12.8%) 315 (69.5%)
Amount of cytoplasm p=0.27
Scant 191 (38.2%) 15 (31.9%) 176 (38.8%)
Moderate 132 (26.4%) 15 (31.9%) 162 (35.8%)
Copicious 177 (35.4%) 17 (36.2%) 115 (25.4%)
Cakir et al. Diagnostic Pathology 2012, 7:145 Page 6 of 11
http://www.diagnosticpathology.org/content/7/1/145
Table 3 Multivariate analysis: Factors significantly
associated with BLBCs on logistic regression analysis
Odds ratio Wald p value 95% CI
Mitotic number 1.098 15.633 <0.001 1.048-1.150
Vesicular chromatin 4.250 8.098 0.004 1.569-11.512
Tubular grade 5.361 6.420 0.011 1.463-19.647
Stromal lymphocytic
response
4.177 4.627 0.031 1.135-15.369
Absence of CIS 2.344 4.274 0.039 1.045-5.255
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(p<0.0001).
Discussion
Basal-like breast carcinoma represents a distinctive group
of invasive breast carcinomas with specific genotype and
immunoprofile. It is associated with poor prognosis and
currently no targeted therapy is available. There are lim-
ited numbers of studies investigating morphological fea-
tures of BLBCs and to date, detailed clinicopathologic
characteristics of the basal-like carcinomas have not been
described in Turkish population [9,10,22,23].
Genetic, ethnic and racial factors influence breast car-
cinoma molecular subtypes, possibly by determining in-
trinsic differences in tumor biology [7]. Basal-like breast
carcinomas are more frequent in African Americans
(26.5%) and in African women (34%) than Non-AfricanFigure 2 Immunohistochemical staining of BLBCs (All photographs w
D. Vimentin.Americans (16.0%) [7,24]. The incidence was lower in
studies from Asia, including Korea, China and Japan
(14.7%, 12.6% and 8.4%, respectively) [25-27]. This study,
in which we believed that the Turkish population can be
reflected, only 45 out of 468 patients with invasive breast
carcinomas (9.6%) exhibited basal-like immunopheno-
type. This incidence rate was similar to the reported
incidences from the east part of the world and an earlier
study from Turkey [22].
Invasive ductal carcinoma was the most frequent
histological subtype identified for the BLBCs in this
study (76.59%), in accordance with the literature
[7,10,27,28]. Although basal-like tumors were usually
shown to have worse prognosis [4,16], several studies
have also revealed that carcinomas known to have a
good prognosis, such as invasive lobular carcinoma, ade-
noid cystic carcinoma and tubular carcinomas, may also
show basal-like phenotype [29-31]. Most of the medul-
lary carcinomas with their favourable outcome, also, had
basal-like phenotype with both GEP and immunohisto-
chemistry [32-34]. The incidence of metaplastic carcin-
omas showing basal-like features ranges from 75 to 95%
in the literature [27,35,36]. In this study, none of the in-
vasive lobular carcinoma and tubular carcinoma cases
was BLBC, but all of the medullary carcinomas (100%)
and 56% of the metaplastic carcinomas had basal-like
immunophenotype. A pleomorphic carcinoma was also
classified as BLBC according to IHC results.ere taken at x100 magnification). A. CK 5/6. B. EGFR. C. CK14.









p value Odds ratio
(95% CI)
CK 5/6 257 (51%) 45 (95.7%) 212 (46.8%)
EGFR 75 (15%) 25 (51.3%) 50 (11%)
CK 14 48 (9.6%) 13 (27.7%) 35 (7.7%) p<0.0001 4.56
(2.20-9.44)
Vimentin 68 (13.6%) 25 (53.2%) 43 (9.5%) p<0.0001 10.83
(5.63-20.82)
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carcinomas was detected as 46 and 59 years, respectively
[7,37]. In this study, the youngest patient with BLBC
was 19 and the oldest was 78 years old. We observed
that BLBCs were seen in slightly younger patients com-
pared to NBBCs (49.3 versus 53.3 years, p=0.04).
Tumor size, lymph node metastasis, local invasion are
important prognostic factors for breast carcinomas. In
most of the studies, it has been shown that BLBCs had
larger tumor size and a tendency for visceral metastases
instead of lymph node metastases [27,28,38-44]. How-
ever, contradictory observations were also present
[9,37,45]. In this study, the size of BLBCs was ranged
from 1 to 8 cm, with an average of 2.8 cm, with no dif-
ference from NBBCs (p=0.47). Lymph node metastasis
rate for BLBCs and NBBCs were similar (54.6% versus
56.4%, respectively, p=0.51).
Identification of multifocality or bilaterality in breast
carcinomas is not uncommon [46,47]. Patients with mul-
tiple tumor foci display higher incidence of lymph node
positivity than unifocal tumors [46,48]. Tot et al. found
that basal-like carcinomas and basal keratin positive
breast tumors are often multifocal (28% and 48%, re-
spectively) [48]. There is only one study that investigated
the relationship between bilateral breast carcinomas and
molecular subtypes and found that basal-like tumors are
frequently discordant with their contra lateral counter-
parts [47]. Another study showed that contra lateral
breast cancer occurred in 25% of recurrences of basal-
like tumors [49]. In this study, among 468 patients, 13
had bilateral breast carcinomas, containing 11 synchron-
ous and 2 metachronous tumors; and another 15
patients had multifocal tumor foci in the same breast. In
2 synchronous bilateral breast carcinomas, there were
discordance between tumor pairs; one side had basal-
like immunophenotype while the contra laterals did not.
One of these NBBCs was ER and PR positive, while the
other one was TN, and both of them did not express
basal keratins, EGFR or vimentin. Two patients with
more than one tumor foci in the ipsilateral breast had
multifocal BLBC. One of these patients had 4 foci, 2 of
which were BLBCs while the other two were TNcarcinomas without expression of basal keratins, EGFR
or vimentin. Other patient had 2 tumor foci and both
were BLBCs. Despite of same hormonal and environ-
mental influences on the ipsilateral and/or contralateral
breast, this heterogeneity may support a stem cell hy-
pothesis on carcinogenesis in which continuing muta-
tions may result in development of different types of
carcinomas. We believe that studies in which stem cell
surface markers are being investigated should be con-
structed to highlight this issue.
The typical histological appearance of BLBCs has been
reported to be a circumscribed, solid lesion with pushing
border and a large central ‘geographic’ necrosis or scler-
osis. They have nuclear pleomorphism with high histo-
logical grade and high mitotic rate (usually more than
40–45 mitosis per 10 HPFs), consistent with their ag-
gressive behavior [7,9,10,27,28,37,50]. Other common
morphological features are stromal lymphocytic re-
sponse, tumor cells with high nucleus to cytoplasmic
ratio, vesicular chromatin and prominent nucleoli
[9,10,23,42,45].
All basal-like tumors, we have analyzed in this study,
were grade 3 with a specificity of 70.2%. The mitotic rate
was also prominently increased, 93% of basal-like
tumors had 15 mitoses and more per 10 HPFs (ranging
from 8 to 60 mitoses/10 HPFs). Most of the tumor cells
were generally disposed in nests, ribbon like and solid
structures with a tubular score of 3 (93.6%). All except
one (97.9%), BLBCs had a nuclear grade of 3. All of the
grading factors were statistically determinant for BLBC
(p<0.0001), supporting that BLBCs are solid, high-grade
tumors with high mitotic count and pleomorphic-
atypical nuclei. In this study, both geographic and cen-
tral necroses were more common in BLBC than NBBC
(respectively, 40.4% vs. 14.5% and 66% vs. 16.1%,
p<0.0001). We observed that large, central acellular
zones can be found in BLBCs, in contrast to the findings
of Livasy et al. [10], although it was not a discriminator
morphology for them (p=0.68). Consistent with the lit-
erature [9,10,23], any degree of stromal lymphocytic re-
sponse was the most common morphological feature for
BLBCs among others investigated in this study (91.5%).
Similarly, patients with basal-like carcinoma had
increased tendency to grow with pushing borders than
NBBC (57.5% versus 15.9% respectively, p<0.0001). Al-
though CIS is regarded as a precursor lesion for most of
the invasive breast carcinomas [2], the reported inci-
dence of accompanying CIS in BLBCs is low [23,48,51].
Compatible with these data, CIS did not accompany to
57.4% of the BLBCs in this study, supporting the idea
that BLBC transforms to invasive cancer in an early
period, without remaining in pre-invasive CIS stage. The
amount of the cytoplasm of the tumor cells did not
show a meaningful difference between BLBCs and
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exhibits these main histological characteristics: high histo-
logic and nuclear grade, lack of tubule formation, frequent
mitotic figures, central and geographic necrosis, pushing
tumor borders and lymphocytic infiltrate. Cytologically,
they have prominent nucleoli and nuclear vesicular chro-
matin. Carcinoma in situ usually does not accompany to
the tumor. Among these features, on multivariate ana-
lyses, the most important factors were mitotic number
(OR: 1.098, p<0.0001), vesicular chromatin (OR: 4.250,
p=0.004), tubule grade (OR: 5.361, p=0.011), stromal
lymphocytic response (OR: 4.177, p=0.031) and absence of
CIS (OR: 2.344, p=0.039). Fulford et al. also performed
multivariate analyses and reported that presence of squa-
mous metaplasia, central scar, tumor necrosis, high mi-
totic count and absence of prominent cytoplasm are
strongly associated with BLBC [9].
Although most of the BLBCs are TN, approximately
71-85% of TN carcinomas have basal-like phenotype
[11,52-54]. In this study, BLBCs constituted 79.7% of
TN carcinomas and this proportion was in the reported
range from previous studies.
Immunohistochemical markers, such as mammoglo-
bulin, ER, PR and CK7, can be used for the detection of
breast origin of a tumor [55]. Some other markers, such
as CK5/6 and CK14, have been shown to be independ-
ently associated with poor outcome when expressed in
breast carcinomas. In non-neoplastic breast ducts, these
two markers are also expressed in the basal layer, so
called basal CKs [56-59]. In this study, 27.6% of the
BLBCs were immunoreactive to CK14 and 95.7% were
to CK5/6. It should be noted that CK5/6 and CK14
expressions were also identified 46.8% and 7.7% of
NBBCs. Restricted expression of CK14 to mature myoe-
pithelial cells and the broader expression of CK5/6 in bi-
potential progenitor cells may explain the difference in
basal keratin expression in the tumors [60]. However,
the frequency of CK5/6 expression in our study was
much higher than the reported series in the literature
[28,56,57]. On the other hand, it has been known that
basal CKs are not expressed in all basal-like tumors clas-
sified by gene microarray analysis [10]. Therefore, we ac-
tually need additional IHC markers to identify basal-like
tumors. Epidermal growth factor receptor (EGFR) is a
member of the c-ERB-B family of tyrosine kinase receptor
proteins, and has a role in tumor cell survival and prolif-
eration [61]. An association between EGFR expression
and the basal like phenotype has been demonstrated in
several studies [10,11]. The expression rates for EGFR ran-
ged from 5% to 65% in breast carcinomas and from 45%
to 72% in BLBCs, depending on the methodology used in
different studies [10,11,27,62-64]. Shao et al. also showed
that immunohistochemical expression of EGFR correlated
with and predicted EGFR amplification [65]. In this study,51.3% of BLBCs were EGFR positive, whereas only 11% of
NBBC cases expressed EGFR. This high percentage of
EGFR expression in BLBCs is important, not only for the
diagnosis of BLBCs, but also in the treatment of this high
grade and TN cancers [65]. Lv et al. showed that EGFR
gene amplification is more frequent than EGFR gene
mutations [64]. We believe that potentially promising
anti-EGFR therapies should be introduced for the cases in
which gene copy numbers were examined by molecular
studies for now, similar to c-ERB-B2.
Vimentin expression in breast carcinomas may have
an association with poor prognosis, hormone receptor
negativity and co-expression of EGFR, which are consist-
ent features for basal-like tumors [66,67]. In several
studies, more than 90% of the basal-like carcinomas
were found to have diffuse and strong vimentin expres-
sion [10,68]. In our series, 53.2% of BLBCs were immu-
noreactive to vimentin, while 9.5% of NBBCs also
showed positivity (p<0.0001). In accordance with the
basal CKs, myoepithelial or stem cell origin and epithe-
lial to mesenchymal transition can explain the vimentin
expression in basal-like tumors [10]. In this study,
vimentin had a concordance of 54.2% with CK5/6 and
79.4% with EGFR (p<0.0001) for BLBCs. If vimentin or
CK14 were included in the IHC panel for identifying
basal-like tumors, three more TN cases would be con-
sidered as BLBCs. Moreover, these high-grade tumors
had similar architectural and/or cytological features to
BLBCs. Therefore; we suggested that vimentin and
CK14 could be added to the diagnostic panel of anti-
bodies to increase the diagnostic accuracy of basal-like
tumors. Moreover, using integrating digital image ana-
lysis, while evaluating multiple IHC markers, can help to
determine subgroups of breast carcinomas more accur-
ate [69].
Conclusion
Basal-like breast carcinomas appear to occur less fre-
quently in Turkish women, which could reflect intrinsic
differences in tumor biology related to racial/ethnic fac-
tors. Synchronously, different molecular subtypes of
breast carcinomas can occur in bilateral and/or multi-
focal breast carcinomas. Light microscopic findings of
the study suggest that there are many significant mor-
phological differences between basal-like and nonbasal-
like breast carcinomas. In addition to these features,
vimentin and CK14 may be used as additional markers
to include in the IHC panel for distinguishing BLBCs.
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